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Abstract 
First-line therapy for most pediatric sarcoma is based on chemotherapy in combination with radiotherapy and surgery. A significant 
number of patients experience drug resistance and development of relapsed tumors. Drugs that have the potential to re-sensitize 
relapsed tumor cells toward chemotherapy treatment are therefore of great clinical interest. Here, we used a drug profiling platform with 
PDX-derived primary rhabdomyosarcoma cells to screen a large drug library for compounds re-sensitizing relapse tumor cells toward 
standard chemotherapeutics used in rhabdomyosarcoma therapy. We identified ABT-263 (navitoclax) as most potent compound 
enhancing general chemosensitivity and used different pharmacologic and genetic approaches in vitro and in vivo to detect the 
NOXA-BCL-XL/MCL-1 balance to be involved in modulating drug response. Our data therefore suggests that players of the intrinsic 
mitochondrial apoptotic cascade are major targets for stimulation of response toward first-line therapies in rhabdomyosarcoma. 
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Introduction 
Chemotherapy has dramatically improved the survival rate of patients 
with different types of tumors. In particular, this includes different pediatric 
tumors such as some leukemia and sarcoma. However, failure of conventional 
treatment in high-risk patients remains a major unsolved clinical problem also 
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in these entities. Responsible for relapse tumor growth is initial or acquired 
resistance to chemotherapy. At the molecular level, a plethora of different 
mechanisms have been identified that can lead to chemoresistance [1] . Hence, 
novel treatment strategies to overcome chemoresistance are urgently needed. 
One potential approach is the use of drugs that re-sensitize cancer cells 
toward first-line chemotherapies (re-sensitizers) when applied as combination 
therapy. Alternatively, first-line therapies might be completely replaced by 
drugs affecting alternative pathways. 
Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue 
sarcoma. RMS is further subdivided based on histologic characteristics into 
several subgroups, with embryonal (ERMS) and alveolar RMS (ARMS) being 
the most frequent ones. While most ARMS harbor the specific fusion proteins 
PAX3/7-FOXO1 (fusion-positive RMS; FP-RMS), ERMS have frequent 
mutations in the RAS pathway but are not associated with fusion proteins 
(fusion-negative RMS; FN-RMS). Despite intense search for more specific 
therapies during the past 2 decades, current first-line treatment regimens 
for RMS are still based on a combination of chemotherapy, radiotherapy 
and surgery. Standard chemotherapy for RMS involves a combination of 
drugs, with vincristine, actinomycin d, and cyclophosphamide (VAC) as 
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backbone, a combination that has not changed for more than 40 y [2] . 
However, 30% of RMS patients relapse and the survival rate of these patients 
is less than 20% [ 3 , 4 ], a situation that has not changed over the past 2 
decades. 
Many potential alternative drugs have been tested in vitro for RMS 
treatment during this time, however no real breakthrough was achieved 
up to now. It is widely accepted that one of the reasons for the high 
rate of failure has been the lack of preclinical models that accurately 
recapitulate all characteristics of human tumors. Especially cell line-based 
models, which have been mainly used in the past, have been questioned. 
They do not represent the heterogeneity of tumor cohorts found among 
human patients and furthermore, during the long time since their generation, 
they underwent a continuous adaption and evolution process in vitro , that 
can lead to a large divergence from the tumors cells they originate from 
[ 5 , 6 ]. However, the development of personalized model systems in the 
recent years including patient-derived xenografts (PDX) and short-term in 
vitro cultures of primary, patient-derived cells in 2D or 3D (organoids or 
spheroids) has set the basis for the discovery of more effective drugs in the 
future [ 7 , 8 ] . 
We recently established a drug profiling platform for primary RMS 
cells [9] . We optimized culture conditions for cells isolated from patient- 
derived xenografts (PDX) or directly from human patient tumors that 
allow continuous propagation of the cells while maintaining their molecular 
characteristics. These cells can be used to evaluate the response toward 
a large collection of drugs in a high-throughput manner. This platform 
therefore represents a step toward more personalized therapies for RMS 
patients. 
Here, we used this platform with cultures from diagnostic and relapse 
samples from the same patients for screening of small molecule re-sensitizers 
to first-line chemotherapeutics. Among 204 tested drugs, we detected the 
BCL-2 family inhibitor ABT-263 (navitoclax) as the most potent re-sensitizer 
of relapse RMS cells toward treatment with vincristine, etoposide and 
doxorubicin. We further validated this finding using different pharmacologic 
and genetic approaches and identified a network of NOXA, MCL-1 and 
BCL-XL as relevant regulator of cell death during combination treatment 
with chemotherapeutics and ABT-263. Finally, we tested the combination of 
ABT-263, and vincristine in a PDX model in vivo . 
Overall, our data suggest that especially BCL-XL and MCL-1 are 
promising drug targets in combination with first-line chemotherapy in RMS. 
Results 
Combination screen identifies ABT-263 as re-sensitizer of recurrent 
PDX-derived primary cells to first-line treatments 
To address the problem of chemoresistance in RMS and generate 
a relevant in vitro model system, we first asked whether PDX-derived 
primary cells (PPCs) could recapitulate patient responses to chemotherapies. 
We tested 2 sets of PPCs (Supplemental Fig. 1) with available pre- 
treatment and post-relapse samples (SJRHB13758_X and SJRHB012) by 
generating dose response curves after 72 hours (h) treatment with different 
chemotherapeutics. In case of SJRHB13758_X, which originates from a 
patient who experienced 21-wk treatment with conventional cytotoxics 
( Fig. 1 A), we observed a clear refractory response to the drugs in recurrent 
cells compared to their diagnostic PPC (increase in IC 50 -doxrubicin > 33.8- 
fold and in IC 50 -etoposide > 39.9-fold; P < 0.01), while in case of SJRHB012 
there was no clear difference between diagnostic and relapse sample ( Fig.1 B- 
C and Supplemental Fig. 2). PDXs from the relapse biopsy of the former 
case (SJRHB13758_X2) grew faster in mice than cells from the diagnostic 
biopsy (SJRHB13758_X1) and reached 100% engraftment (6 out of 6) 
within 28 d compared to 33% engraftment (2 out of 6) after 140 d ( Fig. 1 D), 
respectively, highlighting the more aggressive phenotype of the relapse cancer 
cells. Together, this indicates that our in vitro PPC maintain, and reflect drug 
sensitivities as observed in patients. 
To identify drugs re-sensitizing toward first-line therapy, we used a library 
of 204 drugs which contains experimental compounds covering a broad range 
of molecular pathways as well as many FDA-approved drugs and conventional 
chemotherapeutics. The library in a concentration of 500 nM was combined 
with low dose of standard cytotoxic agents (100 nM doxorubicin (~IC 20 ) 
or 1 µM etoposide (~IC 30 )) in resistant (SJRHB13758_X2C) cells and 
cell viability was assessed 72h post-treatment. We identified 3 drugs which 
reduced cell viability by at least 40% in combination with etoposide and 6 in 
combination with doxorubicin, compared to single treatment ( Fig. 2 A; single 
agents killing more than 90% are not taken into account). Five out of these 
9 drugs target signaling pathways, while 2 directly affect cell death pathways 
(ABT-263 and BV-6). The only candidate shared between the 2 screens was 
ABT-263, an inhibitor of the anti–apoptotic proteins BCL-2/BCL-XL/BCL- 
W. To validate this hit, we performed combinatorial treatments with ABT- 
263 at 250nM and 500nM and 3 chemotherapeutics (doxorubicin, etoposide 
and vincristine). These combinations were highly effective, especially in 
case of vincristine ( Fig. 2 B). Similar effects were observed in a second 
relapse sample (SJRHB012_ZC) ( Fig. 2 C). To assess induction of apoptosis, 
we monitored Caspase 3/7-activity upon co-treatment of ABT-263 with 
doxorubicin (3 to 6h), vincristine (9h) and etoposide (24 to 48h) ( Fig. 2 D, 
2 E and Supplemental Figure S3). This revealed that both relapse PPCs had 
elevated caspase activity when co-treated (~2- to ~18-fold) compared to 
chemotherapy alone. These findings were further corroborated by Western 
blot analysis, which showed increased levels of cleaved Caspase 3/PARP in 
co-treated compared to single treated cells ( Fig. 2 F und 2G). Taken together, 
these data indicate that ABT-263 re-sensitizes recurrent PPCs to conventional 
chemotherapeutics by augmenting apoptosis. 
ABT-263 re-sensitizes RMS cells to chemotherapy via the 
NOXA/BCL-XL axis 
Since ABT-263 antagonizes several pro-survival BCL-2 family members 
including BCL-2, BCL-XL and BCL-W, we next used selective inhibitors 
of either BCL-2 (ABT-199, venetoclax) or BCL-XL (A-1331852). Co- 
treatment with increasing concentrations of doxorubicin and vincristine for 
24h revealed that only pharmacologic inhibition of BCL-XL but not BCL- 
2 could phenocopy the effects of ABT-263 ( Fig. 3 A-D), demonstrating that 
BCL-XL is the relevant player in our PPC models. 
Since also chemotherapy treatment can affect expression of BCL-2 family 
members [10] , we next attempted to dissect the anti–apoptotic factors 
affected by standard chemotherapy. To this aim, we measured expression 
levels of BCL-2 family members after short-term treatment with doxorubicin 
and vincristine by Western Blot. Interestingly, treatment with doxorubicin 
induced a striking down-regulation of MCL-1 expression in 2 recurrent PPCs 
( Fig. 3 E) but only minimally altered levels of BCL-XL or BCL-2. Vincristine 
treatment in contrast did not induce major changes in expression of these 
proteins ( Fig. 3 F). To further substantiate that these observations are relevant 
in combination with ABT-263, we used a lentiviral CRISPR-Cas9 system to 
knock-out BCL-2, BCL-XL and MCL-1 with 2 independent sgRNAs each 
( Fig. 4 A) and treated knock-out cells with ABT-263 for 24h. Remarkably, 
cells lacking MCL-1 exhibited a strongly sensitized drug response consistent 
with previous reports [11] , and phenocopied effects detected in wildtype cells 
upon combination treatment with ABT-263 and standard chemotherapeutics 
( Fig. 4 B). Hence, the data suggest a model where BCL-XL and MCL-1 are 
the 2 major proteins mounting the anti–apoptotic response in recurrent RMS 
cells. To validate this vulnerability, we pharmacologically inhibited both BCL- 
XL and MCL-1 using the specific inhibitors A-1331852 (BCL-XLi) and A- 
1210477 (MCL-1i). This drug combination severely inhibited cell growth 
in a synergistic manner in 3 relapse PPCs, similar to the ABT-263/standard 
chemotherapy treatment ( Fig. 4 C). Importantly, while the combination of 
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Fig. 1. PDX-derived primary cultures from paired diagnostic and relapse rhabdomyosarcoma tumors 
(A) Representation of a case study of a patient at time of diagnosis and relapse. PPCs were derived from corresponding pre- and post-treatment PDX samples 
(SJRHB13758_X1 and SJRHB13758_X2, respectively). 
(B and C, left panel) Dose response curves of diagnostic (SJRHB13758_X1C, blue) and relapse (SJRHB13758_X2C, gray) cells following 72h treatment with 
doxorubicin (B) and etoposide (C). (B and C, right panel) Histogram showing the corresponding IC-50 values for each drug. (Mean ± sd; N = 3; 2-tailed 
unpaired t test; ∗∗P ≤ 0.01). (D, left panel) Tumor growth of diagnostic (blue) and recurrent (gray) PDX samples after implantation in mice (N = 6). (D, 
right panel) Histogram indicating the d of engraftment for individual mice (gray dots) when tumors reached ~100 mm 3 . (Mean ± sd; Mann-Whitney 2-tailed 
t test; ∗P ≤ 0.05) (Color version of the figure is available online.) 
the 2 drugs was very effective, single drug treatments did not significantly 
affect cell viability, resulting in very high BLISS synergy scores of nearly 50 
in 2 samples ( Fig. 4 C). 
We then investigated which of the pro-apoptotic proteins is engaged by 
ABT-263/standard chemotherapy. We initially focused on NOXA, because 
it is a well-known MCL-1 antagonist and has been shown to be involved in 
sensing different types of stress in RMS cells [12-16] . Thus, we knocked- 
out NOXA in SJRHB13758_X2C cells using CRISPR-Cas9 ( Fig. 5 A) 
and assessed both caspase activity and cell viability after combination 
treatment. Interestingly, NOXA depletion significantly attenuated apoptosis 
after short term combination treatment (3 to 24h) of ABT-263 with both 
doxorubicin and vincristine compared to control cells ( Fig. 5 B and 5 C and 
Supplemental Fig. S4A), and rescued cell survival after 72h (vincristine) or 
24h (doxorubicin) ( Fig. 5 D and Supplemental Figure S4B). Consistent with 
this, NOXA protein levels were transiently and shortly (6 to 9h) upregulated 
upon exposure to cytotoxic agents ( Fig. 5 E), correlating with the peak of cell 
death observed at early time points in combinatorial treatments ( Fig. 2 D and 
2 E). 
ABT-263 enhances response to chemotherapeutics in vivo. 
To evaluate the ABT-263/chemotherapy combination in a pre-clinical in 
vivo model of resistant RMS, we treated SJRHB13758_X2 PDX harboring 
mice. We administered ABT-263 for 5 consecutive d (d1 to 5) and vincristine 
for 2 d (d1 and 4) alone and in combination for a total of 3 wk. Although 
we did not achieve tumor regression in any of the mouse cohorts, the 
combination significantly delayed tumor growth and prolonged animal 
survival when compared to vincristine-only treated mice ( Fig. 6 A). Hence, 
these data suggest that ABT-263 combined with first-line therapy can exploit 
the BCL-XL/MCL-1/NOXA axis to delay tumor growth and represents a 
valuable strategy for relapsed FN-RMS patients. 
Collectively, these findings suggest a model whereby chemotherapeutic 
treatment induces NOXA while antagonizing MCL-1, whereas ABT-263 
targets BCL-XL to promote cell death ( Fig. 6 B). 
Overall, the data presented here demonstrate that the mitochondrial 
apoptotic pathway represents a relevant vulnerability in combination with 
standard chemotherapeutics in this molecularly otherwise hard to target 
tumor. 
Discussion 
Using our recently established drug profiling platform for primary 
cultures, we aimed here to identify novel combinatorial therapy options 
for high-risk RMS patients who continue to experience insufficient clinical 
benefit from combinations of standard debulking agents including VAC, 
VAC plus topoisomerase inhibitors or VAC plus carboplatin [2] . We 
identified ABT-263 as the top-scoring drug capable of restoring vulnerability 
to a range of cytotoxic agents (i.e. doxorubicin, etoposide and vincristine) 
and enhancing response to chemotherapy in vivo . ABT-263 resembles the 
structure of the BH3-only protein BAD, thus is designed to induce apoptosis 
by neutralizing the pro-survival function of the BCL-2 family members BCL- 
2, BCL-XL and BLC-W [17] . We found that inhibition of BCL-XL is likely 
to contribute to the cooperativity of ABT-263 with standard chemotherapy. 
This has been demonstrated by the increased sensitivity of PPCs toward 
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Fig. 2. Combination screen identifies ABT-263 as re-sensitizer of recurrent PPCs to first-line treatments 
(A) Heatmap depicting the results of the drug screen aimed at identifying compounds that modulate the sensitivity to doxorubicin (left panel) and etoposide 
(right panel) in SJRHB13758_X2C cells. Top ten hit compounds are depicted in enlarged boxes in the middle. The common candidate (ABT-263) is 
highlighted in red. Numbers refer to cell viability as measured by WST assay and normalized to the vehicle-treated control. 
(B) Viability of SJRHB13758_X2C cells treated with increasing concentrations of etoposide, doxorubicin and vincristine alone (black) or in combination with 
ABT-263 (500nM and 250nM, dark and light blue lines, respectively) for 72h. (Mean ± sd; N = 3-4). (C) Cell viability of SJRHB012_ZC PPCs co-treated 
with or without ABT-263 (250nM and 500nM) and increasing concentrations of doxorubicin (left panel, mean ± sd; N = 2) or etoposide (right panel, mean 
± sd; N = 4) for 72h. (D) Caspase 3/7-activity assay performed in SJRHB13758_X2C cells following treatment with etoposide, doxorubicin and vincristine 
with or without ABT-263 at indicated time points. (Mean ± SD; N = 3; 2-way ANOVA; ∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.001; ∗∗∗∗P ≤ 0.0001). (E) Caspase 
3/7-activity assay following treatment of SJRHB012_ZC cells with indicated chemotherapeutics with or without ABT-263. Time points are also shown. (Mean 
± sd; N = 2-3; 2-way ANOVA; ∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.001; ∗∗∗∗P ≤ 0.0001). (F and G) Western blot analysis showing protein levels of PARP, 
cleaved PARP and cleaved CASPASE 3 after short-term exposure of PPCs to single or combinatorial treatments with indicated compounds. GAPDH was used 
as loading control (Color version of the figure is available online.). 
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Fig. 3. Selective inhibition of BCL-XL mimics the effect of ABT-263 in PPCs. (A-C) Dose response curves of indicated cells co-treated with a selective BCL- 
XL inhibitor (BCL-XLi, A-1331852) at 500nM (light blue) or 1uM (dark blue) and increasing concentrations of doxorubicin (left panel) or vincristine (right 
panel) for 24h. (Mean ± sd; N = 2-3). (D) Cell viability analysis of SJRHB13758_X2C cells co-treated with a specific BCL-2 inhibitor (BCL-2i) (ABT-199) 
at 500nM (orange) or 1uM (red) and doxorubicin (left panel, N = 2) or vincristine (right panel, N = 3) for 24h. (Mean ± sd). (E) Western blot analysis 
showing the expression of indicated proteins after treatment with ABT-263 (500nM) and/or doxorubicin (1 µM and 10 µM) in SJRHB13758_X2C (left panel) 
and SJRHB012_ZC (right panel) cells at indicated time points. β-ACTIN was used as loading control. (F) Western blot analysis showing the expression of 
indicated proteins after treatment with ABT-263 (500nM) and/or vincristine (0.1 µM and 1 µM) in SJRHB13758_X2C (left panel) and SJRHB012_ZC 
(right panel) cells at indicated time points. β-Tubulin was used as loading control (Color version of the figure is available online.). 
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Fig. 4. Genetic interference with BCL-XL phenocopies the effect of ABT-263 in PPCs. (A) Western blot detection of indicated proteins using cell extracts of 
SJRHB13758_X2C cells transduced with CRISPR vectors carrying a scrambled sgRNA (SC) or sgRNAs targeting BCL-2, BCL-XL (left panel) and MCL-1 
(right panel). β-ACTIN was used as loading control. (B) Cell viability assay performed with SJRHB13758_X2C cells depleted of BCL-2 (light and dark blue 
lines), BCL-XL (red and orange lines) and MCL-1 (light and dark green lines) and treated with increasing concentrations of ABT-263 for 24h. (Mean ± sd; 
N = 2-3). (C) Cell viability of indicated cells upon treatment with a BCL-XLi (A-1331852) and a MCL-1 (MCL-1i, A-1210477) inhibitor for 72h. (Mean 
± sd; N = 3) (Color version of the figure is available online.). 
doxorubicin and/or vincristine upon pharmacologic interference with BCL- 
XL and expands the relevance of BCL-XL also to FN-RMS, besides its 
well-recognized role as modulator of the anti–apoptotic function of PAX3- 
FOXO1 in FP-RMS [18] . Similar findings have recently been reported in 
RMS cell lines [19] and are in agreement with other studies that collectively 
suggest that BCL-XL together with MCL-1 are the more important pro- 
survival proteins in solid tumors, whereas BCL-2 is more relevant in 
some leukemia like AML [20] . Indeed, we found BCL-2 to be largely 
dispensable for the observed phenotype, but detected a functional role 
for MCL-1 in FN-RMS. We found that the dual inhibition of BCL- 
XL and MCL-1 represents a “druggable” vulnerability in recurrent PPCs, 
suggesting that the 2 proteins have redundant functions. This has recently 
also been described in cell lines of different types of sarcoma including 
RMS as well as in a range of other solid tumors including melanoma, 
breast, and lung cancer [21-24] . Clinically, however, such a combination 
might be problematic due to acute liver toxicity recently detected in mouse 
models [23] . 
Our PPCs have been molecularly characterized to resemble primary 
tumors more closely than established cell lines [9] . Hence, expression of BCL- 
2 family members is also expected to play an important role in human patient 
tumors. In support of this, overexpression of Mcl-1 RNA in 14 primary RMS 
tumors has been recognized earlier [25] and suggested as novel therapeutic 
target in sarcomas [26] . Similarly, high level of BCL-XL expression was 
detected by immunohistochemistry in > 60% of RMS tumors (data not 
shown) and dynamic BH3 profiling predicted chemotherapy sensitivity in 
3 RMS cell lines [27] , supporting our notion of re-sensitization to first-line 
therapy. 
Our molecular studies further revealed that ABT-263 augments the 
cytotoxicity of conventional chemotherapeutics via an axis that at least 
partially relies on NOXA. While NOXA knock-outs did not completely 
rescue from apoptosis, suggesting that to some extent also other pro- 
apoptotic players are involved, we did not find any cell death alteration 
in BIM knock-out cells treated with either ABT-263 alone or with 
chemotherapy (data not shown), albeit BIM has been proposed as a 
key determinant of the sensitivity to ABT-263 in a large collection of 
cancer cell lines [28] . NOXA has already been recognized as a major 
stress sensor in both FP-RMS and FN-RMS, initiating mitochondrial 
apoptosis downstream of several types of treatments [ 12-16 , 29 ]. This 
suggests that NOXA is the main BH3-only stress sensor in most RMS 
cells. 
Interestingly, when performing the combination screens with doxorubicin 
and etoposide, the compounds BV-6 and birinapant were identified as 
additional hits, respectively. Both these drugs are second mitochondria- 
derived activator of caspase (SMAC) mimetics, a type of drug with 
similarity to the SMAC family of proteins targeting inhibitor of 
apoptosis proteins (IAPs). Blockade of IAPs therefore releases breaks 
active in the apoptotic cascade. Hence, SMAC mimetics potentially 
offer another opportunity for re-sensitization of RMS toward first-line 
therapies. 
From a clinical point of view, BH3-mimetics (ABT-263, its predecessor 
ABT-737 or the selective BCL-2 inhibitor ABT-199) have previously 
been shown to potentiate the efficacy of a variety of clinically relevant 
compounds in a large set of cancer entities [ 17 , 28 , 30-34 ]. Unfortunately, 
in contrast to ABT-199, which is well tolerated and clinically approved for 
the treatment of different types of leukemia, early clinical tests of ABT- 
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Fig. 5. NOXA is a relevant player of the ABT-263-mediated sensitization to chemotherapy. (A) Western blot analysis for validation of NOXA protein depletion 
upon transduction of SJRHB13758_X2C cells with CRISPR vectors containing sgRNAs targeting NOXA (sg1 and sg2). β-ACTIN was used as loading control. 
(B) Caspase 3/7 assay performed with SJRHB13758_X2C NOXA knock-out cells (sg1, upper panel and sg2, lower panel) upon co-treatment with vincristine 
and ABT-263 (500nM and 250nM) for 24h. (Mean ± sd; N = 3; 2-way ANOVA; ∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.001; ∗∗∗∗P ≤ 0.0001; NS, not significant). 
(C) Caspase 3/7 assay performed on SJRHB13758_X2C NOXA knock-out cells upon co-treatment with doxorubicin and ABT-263 (500nM and 250nM) 
for 3 hours. (Mean ± sd; N = 3; 2-way ANOVA; ∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.001; ∗∗∗∗P ≤ 0.0001; NS, not significant). (D) WST-1-assay performed 
on SJRHB13758_X2C NOXA knock-out cells upon treatment with increasing concentrations of vincristine for 72h. (E) Western blot detection of MCL-1, 
NOXA, and BCL-2 using extracts from SJRHB13758_X2C cells treated with either doxorubicin (left) or vincristine (right) for 3, 6, 9, 24, and 48 hours (H). 
GAPDH was used as loading control. 
263 have shown that it induces thrombocytopenia via on-target effects in 
platelets, limiting its clinical use [35] . However, combinatorial approaches 
as described here open the possibility to use lower doses that might spare 
platelets to a large extent. Furthermore, recent studies with a PROTAC- 
version of ABT-263, mediating BCL-XL degradation via recruitment to the 
von Hippel-Lindau (VHL) E3 ligase, have shown that in such an approach 
platelets are much less affected by the drug, since these do not express 
VHL [36] . 
Taken together, these results strongly suggest that clinical use of BCL- 
XL directed drugs should be reconsidered in the future for therapy of 
RMS. 
Material and methods 
PDX transplantation 
PDX tumors were transplanted as described previously [9] . For tumor 
amplification, pieces with a size of ~10 to 30 mm 3 from fresh human tumor 
biopsies or established PDX tumors were transplanted subcutaneously into 
the flank of 6 to 10 wk old, sex-matched NOD scid gamma (NSG) mice. 
Engraftment of tumors was monitored by tumor size measurements 3 times 
a wk using a caliper. Tumors were isolated when they reached a size of ~1000 
mm 3 . 
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Fig. 6. ABT-263 augments the effect of chemotherapy in vivo . (A, left panel) Tumor growth curves of SJRHB13758_X2 PDX following vehicle application 
(black line) or treatment with ABT-263 only (red line), vincristine only (dark blue) and the combination (light blue). Gray color indicates time of therapy (3 
wk). (Mean ± sem; N = 6; 2-way ANOVA; ∗∗∗∗P ≤ 0.0001). (A, right panel) Sur vival cur ve of mice from left panel. (Log rank (Mantel-Cox) test; ∗P ≤ 0.05; 
∗∗P ≤ 0.01; ∗∗∗P ≤ 0.001; ∗∗∗∗P ≤ 0.0001). (B) Scheme depicting the proposed molecular mechanism underlying the effect of the ABT-263/chemotherapy 
combination (Color version of the figure is available online.). 
For in vivo drug treatment, a single cell suspension of dissociated PDX 
tumors containing 0.7 to 5 ∗10 6 cells was injected subcutaneously into the 
flank of sex matched, 6 to 10 wk old NSG mice. 
Culture of PDX cells 
PDX-derived cells were cultured in vitro as described previously [9] . 
Briefly, FN-RMS PDX cells were cultured on matrigel- or gelatin- 
coated dishes in NB medium (Thermofisher Scientific, 21103049), 
supplemented with 2xB-27 (Thermofisher Scientific, 17504044), 100 U/mL 
penicillin/streptomycin and 2 mM glutamax (Life technologies, 35050-061). 
Three times per wk, medium was replaced with fresh one. When reaching 
confluency, cells were detached using Accutase (Sigma-Aldrich, A6964), and 
splitted in a ratio of 1:2 to 1:3. 
For matrigel-coating, matrigel (Corning, 354234) was diluted 1:10 in NB 
medium and left on the dish for 30 to 60 min at RT. Before cell-plating, excess 
matrigel solution was removed. For gelatin-coating, a 2% solution of gelatin 
(Sigma-Aldrich, G9391) in water was left on the dish for 2h at 37 °C. The 
solution was then removed and the plates were dried at RT for 30 to 60 min. 
Drug profiling 
For drug profiling, 3000 to 20000 PPCs were plated per 384 well. The 
next d, medium was changed, and cells were incubated with a drug library 
containing 204 different drugs (Selleckchem) in a concentration of 500 nM 
alone or together with 100 nM vincristine or 1 µM etoposide in duplicate 
wells for 72 h. 12 wells treated with DMSO on each plate served as controls. 
Cell viability was then determined by WST-1 assay (Roche, 11644807001). 
A list of compounds employed in this study is provided in Supplemental table 
1. 
Drug response curves 
For IC 50 determination 3000 to 20000 PDX cells were plated per 384 
well. The next d, medium was changed, and cells were incubated with the 
drug in a logarithmic concentration range between 0.006 and 10 µM using a 
digital dispenser (HP D300). After 72h cell viability was measured by WST-1 
assay. 
Caspase 3/7-activity assay 
Cells were seeded in white 384-well plates with clear bottom (Greiner 
Bio-One, #781098). Caspase activity was determined at indicated time 
points by Caspase-Glo 3/7 Assay (Promega, #G8093) according to 
the manufacturer’s instructions. Luminescence was measured using the 
multidetection microplate reader Synergy HT (Bio-Tek Instruments). 
In vivo drug treatment 
Tumors were established from dissociated PDX and tumor harboring mice 
were randomized into treatment and control cohorts of 6 animals when the 
tumor average size reached about 100 mm 3 . ABT-263 (ApexBio, A3007) was 
dissolved in a mixture of 10% EtOH, 30% PEG-400 (Lipoid) and 60% 
phosal 50 PG (Sigma Aldrich) and was given orally (100 mg/kg) alone or 
1.5 h after standard chemotherapy in combination experiments. Compound 
solution was prepared fresh before drug administration and any remaining 
solution was routinely stored at + 4 °C for no longer than 1 wk. Vincristine 
(Teva) was injected intravenously (i.v.) (0.5 mg/kg). Tumor size was measured 
3 times a wk using a caliper and mouse weight was measured twice a wk. 
No mice needed to be euthanized due to severe body weight loss ( > 20% 
than baseline). All animal experiments were performed under license of the 
authorities of the Kt. Zürich (206/15). 
Generation of gene knock-outs by CRISPR-Cas9 
Single guide RNAs were designed using the CRISPOR online design 
tool and cloned by Golden Gate cloning into the plentiCRISPR-EGFP 
vector (Addgene #75159). Lentiviral particle generation was performed 
as previously described [37] . Target cells were transduced with sgRNA 
constructs with an efficiency of 80% to 90%. Cells were then cultured for 
at least 1 wk before knock-out efficiency was determined by Western Blot 
and physiological experiments were performed. 
SgRNA sequences (without protospacer adjacent motif (PAM)): 
SCRAMBLED: GCACTACCAGAGCTAACTCA 
MCL-1 sg1: CTCAAAAGAAACGCGGTAAT 
MCL-1 sg2: TGGAGACCTTACGACGGGTT 
BCL-XL sg1: CAGTGGCTCCATTCACCGCG 
BCL-XL sg2: GGGTTGCCATTGATGGCACT 
BCL-2 sg1: GAGAACAGGGTACGATAACC 
BCL-2 sg2: GTCGCAGAGGGGCTACGAGT 
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NOXA sg1: ACGCTCAACCGAGCCCCGCG 
NOXA sg2: TCGAGTGTGCTACTCAACTC 
Western blot 
Generation of cell lysates using RIPA buffer and protein detection 
by Western blot was performed as described previously [38] {Bohm, 2016 
#30}. Antibodies used in this study included: anti–GAPDH (#2118S; Cell 
Signaling), anti–PARP (#9542S; Cell Signaling), anti–cleaved CASPASE 
3 (#9664P; Cell Signaling), anti–BCL-XL (#2762S; Cell Signaling), anti–
MCL-1 (#5453T; Cell Signaling), anti–NOXA (#14766S; Cell Signaling), 
anti β-ACTIN (#12262S, HRP-conjugated; Cell Signaling) and anti–BCL- 
2 (#M0887; Dako). All primary antibodies were diluted 1:1000 in milk. For 
secondary antibodies, HRP-linked anti–mouse IgG (Cell Signaling, #7076S) 
and HRP-linked anti–rabbit IgG (Cell Signaling, #7074S) were used at 
1:5000 dilution in milk. 
Bioinformatic analysis and statistics 
Data analysis was performed using GraphPad Prism (version 6). Statistic 
tests and number of biological replicates (N) per each experiment are 
outlined in figure legends. BLISS synergy scores were calculated using the 
Synergyfinder webtool ( https://synergyfinder.fimm.fi) 
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